Trial
NCT02770014
Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Dana-Farber Cancer Institute
Collaborators
Astellas Pharma Inc
Condition
Epidermal Growth Factor Receptor
Intervention
Erlotinib
Why stopped
Terminated due to Osimertinib approval
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-11-22